source
- CMS proposes changes to curb 340B drug discount program’s costly subsidies to safety-net hospitalsCasey B. Mulligan, chief economist and chief regulatory officer at HHS, wrote an opinion piece outlining a major flaw in the 340B drug discount program. The program, created in 1992, gives steep di…
- ARM playbook proposes data reuse to slash gene-editing R&D costs and broaden rare-disease therapiesThe Alliance for Regenerative Medicine released a new playbook that outlines how developers of gene‑editing therapies can reuse existing data to lower research and development expenses. The guidanc…